Company Analysis
Sign in

CytomX Therapeutics, Inc. (CTMX)

Nasdaq: CTMX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2010
Full chart Alerts Compare
Grade4.4
◀ Past 3.4● Present 5.8▶ Future 3.6
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$76.2M-44.8%
Net income-$17.4M-154.5%
Earnings per sharen/a
Operating cash flow-$75.6M+12.3%
Cash$12.7M-66.7%
Debtn/a
Shareholders’ equity$99.0M+21812.3%
Shares, diluted137.9M+62.8%
Return on equity-17.5%
The recordfrom its filings
Filings in 202659
Newest filingNov 10 · SCHEDULE 13G
Annual reportMar 16, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 16
Insider sales, 12 months$2.2M
Insider buys, 12 months$0.00
Patents granted86
Filer categoryAccelerated filer
Trailing twelve months to Sep 2026Revenue $14.0MNet income -$85.4MCash from operations -$50.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Aug 7, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Aug 6, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton CTMX · research, not advice